MRK · News · 20261104N
Regulatory Approval Milestones
Merck & Co., Inc. · 2026-11-04 · Importance null · Surprise null · In source text
The U.S. Food and Drug Administration granted emergency use authorization for Merck’s Bravecto to treat new screwworm infestations in dogs and puppies. The authorization expands the U.S. use of Bravecto chewable tablets, which were already available for treating and preventing certain flea infestations. The report provides no financial estimate or timeframe for the authorization’s commercial impact.
Key facts
- Merck's Bravecto received emergency use authorization from the U.S. FDA to treat new screwworm infestations in dogs and puppies. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | Merck's Bravecto received emergency use authorization from the U.S. FDA to treat new screwworm infestations in dogs and puppies. |